Deep Sequencing and Analysis of Pharmacogenomic Regions: Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01)

Post Date

January 25th 2010

Application Due Date

April 29th 2010

Funding Opportunity Number

RFA-DA-10-019

CFDA Number(s)

93.279

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Award Range:

  $None - $250000

Grant Description

Purpose. Genome-wide association studies (GWAS) have been critical for identifying genomic regions associated with addiction phenotypes, and have highlighted several areas that require further refinement using deep sequencing approaches. The goal of this FOA is to support studies proposing to use next-generation sequencing technologies to identify the structural variants and SNP variants with rare to moderate frequencies that affect addiction risk in well-characterized samples with drug abuse phenotypes. Applications may propose strategies for deep sequencing based on family based designs; deep sequencing of regions identified by GWAS to be associated with addiction risk; sequencing candidate genes in individuals with extreme phenotypes; or other analytic approaches that capitalize on the genetic architecture. Applicants must use existing DNA samples with appropriately obtained consents for broad data sharing.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-019.html